About Haemostatix
Haemostatix is a company based in Nottingham (United Kingdom) founded in 2003 was acquired by Ergomed in May 2016.. Haemostatix has raised $2.43 million across 6 funding rounds from investors including University of Leicester, Royal Society of Chemistry and Albion Capital. The company has 11,995 employees as of December 31, 2020. Haemostatix operates in a competitive market with competitors including QBiotics, MediWound, Ilya Pharma, Resolution Therapeutics and ProFibrix, among others.
- Headquarter Nottingham, United Kingdom
- Employees 11995 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Haemostatix Limited
- Date of Incorporation 14 Mar, 2003
- Jurisdiction GUILDFORD, ENGLAND
-
Annual Revenue
-
Net Profit
$-199.58 K (USD)69as on Dec 31, 2020
-
EBITDA
-
Total Equity Funding
$2.43 M (USD)
in 6 rounds
-
Latest Funding Round
$31.47 K (USD), Grant
Jun 29, 2015
-
Investors
University of Leicester
& 10 more
-
Employee Count
11995
as on Dec 31, 2020
-
Acquired by
Ergomed
(May 04, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Haemostatix
Haemostatix has successfully raised a total of $2.43M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $31.47 thousand completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $31,473
-
First Round
First Round
(05 Nov 2010)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2015 | Amount | Grant - Haemostatix | Valuation |
investors |
|
| Nov, 2012 | Amount | Series A - Haemostatix | Valuation | Catapult Ventures , Spark Ventures |
|
| Oct, 2012 | Amount | Grant - Haemostatix | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Haemostatix
Haemostatix has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include University of Leicester, Royal Society of Chemistry and Albion Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment solutions are provided by Catapult Ventures for growth.
|
Founded Year | Domain | Location | |
|
Early-stage tech and life science investments are made in Europe.
|
Founded Year | Domain | Location | |
|
Venture capital investments are managed by Albion Capital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Haemostatix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Haemostatix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Haemostatix Comparisons
Competitors of Haemostatix
Haemostatix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as QBiotics, MediWound, Ilya Pharma, Resolution Therapeutics and ProFibrix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Small molecules from plant extracts are developed for medical applications.
|
|
| domain | founded_year | HQ Location |
Enzymatic therapies for tissue repair and regeneration are developed.
|
|
| domain | founded_year | HQ Location |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| domain | founded_year | HQ Location |
Macrophage cell therapies are developed for inflammatory and liver diseases.
|
|
| domain | founded_year | HQ Location |
Powdered fibrin sealant for surgical bleeding
|
|
| domain | founded_year | HQ Location |
Topical formulations for corneal wounds, ulcers, and scars are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Haemostatix
When was Haemostatix founded?
Haemostatix was founded in 2003 and raised its 1st funding round 7 years after it was founded.
Where is Haemostatix located?
Haemostatix is headquartered in Nottingham, United Kingdom.
Is Haemostatix a funded company?
Haemostatix is a funded company, having raised a total of $2.43M across 6 funding rounds to date. The company's 1st funding round was a Grant of $2.25M, raised on Nov 05, 2010.
How many employees does Haemostatix have?
As of Dec 31, 2020, the latest employee count at Haemostatix is 11,995.
What does Haemostatix do?
Haemostatix has developed a new class of peptide-based coagulant, or haemostat, for the control of bleeding. The company has pioneered a new approach to haemostasis that is based on a peptide that binds to the protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical products to treat surgical bleeding. Haemostatixs pipeline includes PeproStat Liquid, a topical liquid haemostat that is applied to wounds to control bleeding during surgery; and HXP12 ReadyFlow, a flowable and transparent haemostatic gel that can be applied to irregular bleeding sites.
Who are the top competitors of Haemostatix?
Haemostatix's top competitors include Ilya Pharma, QBiotics and Tempo Therapeutics.
Who are Haemostatix's investors?
Haemostatix has 11 investors. Key investors include University of Leicester, Royal Society of Chemistry, Albion Capital, Ergomed, and Catapult Ventures.